Cost of illness of patient-reported adverse drug events: A population-based cross-sectional survey

BMJ Open

Volumn 3, Issue 6, 2013, Pages

  Gyllensten, Hanna ^a   Rehnberg, Clas ^b   Jönsson, Anna K ^c   Petzold, Max ^d   Carlsten, Anders ^a,e   Sundell, Karolina Andersson ^a,d  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADULT; ADVERSE DRUG REACTION; ARTICLE; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DENTAL PROCEDURE; FEMALE; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; MALE; PHARMACY; PRIMARY MEDICAL CARE; SELF REPORT;

EID: 84880434009     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002574     Document Type: Article

References (40)

1. Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995;10:199-205.
2. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-40. (Pubitemid 23225664)
3. Krähenbühl-Melcher A, Schlienger R, Lampert M, et al. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 2007;30:379-407. (Pubitemid 46740336)
4. Rodríguez-Monguió R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003;21:623-50. (Pubitemid 36808215)
5. Gyllensten H, Jönsson AK, Rehnberg C, et al. How are the costs of drug-related morbidity measured? A systematic literature review. Drug Saf 2012;35:207-19.
6. Isacson D, Johansson L, Bingefors K. Nationwide survey of subjectively reported adverse drug reactions in Sweden. Ann Pharmacother 2008;42:347-53. (Pubitemid 351429599)
7. Segel JE, ed. Cost-of-Illness studies-a primer. RTI-UNC Center of Excellence in Health Promotion Economics, 2006:1-39.
8. Hakkarainen KM, Andersson Sundell K, Petzold M, et al. Self-reported adverse drug events equally prevalent across age groups-a population-based survey in Sweden. Manuscript submitted for publication.
9. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005;28:851-70. (Pubitemid 41428543)
10. Yu K, Nation R, Dooley M. Multiplicity of medication safety terms, definitions and functional meanings: when is enough? Qual Saf Health Care 2005;14:358-63. (Pubitemid 41495123)
11. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
12. European Parliament, Council of the European Union. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. OJ 2010;L 348:74-99.
13. Young AM, Glover N, Havens JR. Nonmedical use of prescription medications among adolescents in the United States: a systematic review. J Adolesc Health 2012;51:6-17.
14. Taylor S, Abramowitz JS, McKay D. Non-adherence and non-response in the treatment of anxiety disorders. J Anxiety Disord 2012;26:583-9.
15. Al-Olah YH, Al Thiab KM. Admissions through the emergency department due to drug-related problems. Ann Saudi Med 2008;28:426-9.
16. Gandhi TK, Seger DL, Bates DW. Identifying drug safety issues: from research to practice. Int J Qual Health Care 2000;12:69-76. (Pubitemid 30141024)
17. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556-64. (Pubitemid 36437933)
18. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
19. Swedish Association of Local Authorities and Regions Editor. Statistik om hälso-och sjukvård samt regional utveckling 2010. Sveriges kommuner och landsting, Stockholm, 2011:1-216. ISBN:978-91-7164-683-5. Swedish.
20. Swedish Association of Local Authorities and Regions Editor. Kostnad per brukare: jämförelser mellan kommuner inom omsorg om äldre och personer med funktionsnedsättning: utfall 2010. Sveriges kommuner och landsting, Stockholm, 2011:39. ISBN: 978-91-7164-722-1. Swedish.
21. Transport Analysis Editor. Special transport service and inter-municipal transport service 2010. Trafikanalys, Stockholm, 2011. Report: 2011:16. Swedish.
22. Transport Analysis Editor. Local and regional public transport 2010. Trafikanalys, Stockholm, 2011. Report: 2011:19. Swedish.
23. Lindgren B. Costs of illness in Sweden 1964-1975. Lund, Sweden: Lund University, 1981.
24. Statistics Sweden. Genomsnittlig grund-och månadslön samt kvinnors lön i procent av mäns lön efter sektor, yrke (SSYK), kön och ålder. År 2005-2010. http://www.ssd.scb.se/databaser/ makro/Visavar.asp?yp=tansss&xu=C9233001&omradekod=AM& huvudtabell=LonYrkeAlder4&omradetext=Arbetsmarknad&tabelltext= Genomsnittlig+grund%2D+och+m%E5nadsl%F6n+samt+kvinnors+l %F6n+i+procent+av+m%E4ns+l%F6n+efter+sektor%2C+yrke+%28SSYK%29%2C+k%F6n+och+%E5 lder%2E+%C5r&preskat=O &prodid=AM0110&deltabell=&deltabellnamn= Genomsnittlig+grund%2D+och+m%E5nadsl%F6n+samt+kvinnors+l%F6n+i+procent+av+m %E4ns+l%F6n+efter+sektor%2C+yrke+%28SSYK%29%2C+k%F6n +och+%E5lder%2E+%C5r& innehall=Antal&starttid=2005&stopptid=2010&Fromwhere=M&lang= 1&langdb=1 (accessed 6 Mar 2012)
25. Statistics Sweden. Mer om Arbetskostnadsindex (AKI). Swedish. http://www.scb.se/Pages/Standard-23066.aspx (accessed 26 Nov 2012).
26. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36.
27. EuroQol Group. EQ-5D-5L Crosswalk Value Sets. 2012. http://www.euroqol. org/about-eq-5d/valuation-of-eq-5d/eq-5d-5l-value-sets.html (accessed 26 Nov 2012).
28. Organisation for economic co-operation and development. PPPs and exchange rates. http://stats.oecd.org/Index.aspx? DataSetCode=CPL# (accessed 24 Sep 2012).
29. Evans DB, Edejer TT, Adam T, et al. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ 2005;331:1137-40.
30. Leuven E, Sianesi B, eds. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Boston College Department of Economics. Report: April 2012 revision, 2003. http://ideas.repec.org/c/boc/bocode/s432001.html
31. Suominen S, Koskenvuo K, Sillanmaki L, et al. Non-response in a nationwide follow-up postal survey in Finland: a register-based mortality analysis of respondents and non-respondents of the Health and Social Support (HeSSup) Study. BMJ Open 2012;2:e000657.
32. Morimoto T, Gandhi TK, Seger AC, et al. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004;13:306-14. (Pubitemid 39070900)
33. Zhu J, Stuver SO, Epstein AM, et al. Can we rely on patients' reports of adverse events? Med Care 2011;49:948-55.
34. Ramsberg J, Ekelund M. Stuprörstänkande gör samhällets kostnader för ohälsa onödigt höga. Ekonomisk debatt 2011;39:41-53. Swedish.
35. Thomas EJ, Studdert DM, Newhouse JP, et al. Costs of medical injuries in Utah and Colorado. Inquiry 1999;36:255-64.
36. Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother 2011;45:977-89.
37. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related resource use. A study of community-dwelling persons 65 years of age and older. Ann Intern Med 1992;117:634-40.
38. Gautier S, Bachelet H, Bordet R, et al. The cost of adverse drug reactions. Expert Opin Pharmacother 2003;4:319-26. (Pubitemid 36367555)
39. Burton MM, Hope C, Murray MD, et al. The cost of adverse drug events in ambulatory care. AMIA Annu Symp Proc 2007:90-3.
40. Lundkvist J, Jönsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004;18:275-80. (Pubitemid 38758694)